Prostate Cancer

The Deyo/Charlson co-morbidity index (CCI) and Klabunde co-morbidity index (KCI) co-morbidity indexes represent outdated indexes when the endpoint of complications after radical prostatectomy (RP) is considered. A novel group of co-morbidities derived from International Classification of Diseases-9 diagnostic codes in a contemporary RP database could provide better accuracy. Research Design, Subjects and Measures: We relied on 20,484 patients with clinically localized non-metastatic prostate cancer treated with RP between 2000 and 2009 in the Surveillance, Epidemiology, and End Results-Medicare linked database. We examined 2 endpoints, namely, 90-day medical complication rate and 90-day surgical complication rate after RP. Simulated annealing (SA) was used to develop a novel co-morbidity index. Finally, the newly identified groups of co-morbid conditions were compared with the CCI and Klabunde indexes. Our SA identified 10 and 7 individual co-morbid conditions able to predict 90-day m

Phoenix, Arizona (UroToday.com) Ji Youl Lee, MD, of Seoul St. Mary’s Hospital, was the WUOF Invited Lecturer today. His talk was a brief overview of the potential of artificial intelligence and technology in the management of prostate cancer. He set the talk in the context of work he is doing in Korea. The current trend in medicine is an increasing push towards precision medicine, using Big Data (bioinformatics), smart medicine, and artificial intelligence. Technology is creeping into all aspects of our lives and hospitals and medical care are no exception – smart hospitals are the future. The key lies in harnessing all the data gathered in an efficient manner to inform medical care and improve patient outcomes. A “Smart Hospital” is built on an ICT environment of interconnected assets (the Internet of Things) aimed at improving treatment outcomes and patient convenience. It relies on Big Data Revolution – ‘the Fourth Industrial Revolution’ – which combines connected devices with clo

“Some people come to us after they have tried herbal medicine without success, when the disease has progressed to other organs." “Some people come to us after they have tried herbal medicine without success, when the disease has progressed to other organs." HEALTH Ugandan men are hesitant to undergo prostate cancer checks out of fear of discovering they have cancer, limiting chances of detecting the disease early. Prostate cancer is the leading form of cancer among men and second-leading cause of cancer deaths in Uganda. Globally, an estimated 300,000 people are living with prostate cancer. Dr Henry Dabanja, a urologist at Mengo Hospital, said most of the people who submit to the checks seek treatment when the disease is in its advanced stages and difficult to treat. “Some people come to us after they have tried herbal medicine without success, when the disease has progressed to other organs. On average, 70% of the cases die." Dabanja was addressing civil se

Speech to Text for Prostate Cancer: Ron Brown's Story Below is the closed-captioning text associated with this video. Since this uses automated speech to text spelling and grammar may not be accurate. think about prostate cancer has changed dramatically in recent years. this is what one well known rogue valley resident recently found at the time when they were ready to start treatment, it was up to 12. all of a sudden it had gone up to six and it had doubled again in 6 months up to 12. and so it was obvious something was happening and it wasn't going back down, it was going up. and so that's when they did the biopsy." a doctors test confirmed the worst. he did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer. and indicated it was starting to spread to the lymph nodes." and those numbers that indicated something was going on? 1 th ey're called a psa. i asked dr. kadi ann bryan with rogue valley urology about them. ps

Men diagnosed with low- or intermediate-risk prostate cancer were willing to sacrifice some survival time in exchange for improvements in quality of life (QoL), according to findings from the COMPARE trial, which were presented at the 2018 National Cancer Research Institute (NCRI) Conference, Glasgow, United Kingdom. 1 Specifically, surveyed men were willing to trade off on survival for fewer further treatments following initial therapy, a greater chance of maintaining urinary continence, and a higher chance of maintaining erectile function. The study was presented by Hashim Ahmed, PhD, chair and professor of urology, Imperial College London, and chair of NCRI's Prostate Cancer Clinical Studies Group. Continue Reading Below The COMPARE study used a discrete choice experiment (DCE) designed to elicit patient preferences for managing localized prostate cancer. The DCE included variables such as type of treatment, return to day-to-day activities, sexual function, urinary fun

November 29, 2018 Share this content: Men with Gleason score 9 to 10 prostate cancer derive no significant survival benefit from androgen deprivation therapy. Gleason score 9 to 10 prostate cancer (PCa) may be less sensitive to androgen deprivation therapy (ADT) than Gleason 8 disease, new study findings in European Urology suggest. Paul L. Nguyen, MD, of Harvard Medical School in Boston, and his collaborators identified 20,139 men from the National Cancer Database with localized or locally advanced Gleason score (GS) 8 to 10 PCa treated with external beam radiation therapy (EBRT) . Of these, 60% had GS 8, 36% GS 9, and 4% GS 10 disease. In addition to radiation therapy, 78% of GS 8 and 87% of GS 9 to 10 patients received ADT. Continue Reading Below ADT was associated with a significant 22% decreased risk for death among patients with GS 8 cancer, but was not associated with improved survival among patients with GS 9 to 10 cancer in multivariable analysis. As GS increased

Researchers are of the belief that incidence of prostate cancer is likely to double by 2020. There is a need to increase talks and discussions regarding early signs, symptoms, risk factors and detection of prostate cancer. IANS quotes experts as saying that prostate cancer is a cancer which grows slowly. It can be cured if a person is detected with it at an early stage. As per the Indian Medical Council of Research, prostate cancer is the second leading cancer among males in cities like Pune, Kolkata, Delhi and Thiruvananthapuram. It is the third leading cancer in cities like Mumbai and Bengaluru. Prostate cancer is likely to go undetected as the symptoms include difficulty in passing urine, burning sensation while passing urine and increased frequency of urination. All these symptoms are ignored since they are thought to be a normal part of ageing. It is thus important for people above the age of 40 to get screening for prostate cancer every year. Prostate cancer can sometimes occ

Speech to Text for Prostate Cancer: Ron Brown's Story Below is the closed-captioning text associated with this video. Since this uses automated speech to text spelling and grammar may not be accurate. think about prostate cancer has changed dramatically in recent years. this is what one well known rogue valley resident recently found at the time when they were ready to start treatment, it was up to 12. all of a sudden it had gone up to six and it had doubled again in 6 months up to 12. and so it was obvious something was happening and it wasn't going back down, it was going up. and so that's when they did the biopsy." a doctors test confirmed the worst. he did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer. and indicated it was starting to spread to the lymph nodes." and those numbers that indicated something was going on? 1 th ey're called a psa. i asked dr. kadi ann bryan with rogue valley urology about them. ps

GOLD HILL, Ore. -- A prostate cancer diagnosis can be scary for any man. Ron Brown sat down with Mike Duffy to share his story of diagnosis and treatment. He also explained why he believes early detection is so important. "At the time when they were ready to start treatment, it was up to 12," explained Brown. All of a sudden it had gone up to six and it had doubled again in six months up to 12. So it was obvious something was happening and it wasn't going back down, it was going up." A doctor's test confirmed the worst. "He did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer," detailed Brown. "It indicated it was starting to spread to the lymph nodes." Those numbers Ron referenced are called a PSA. Dr. Kadi-Ann Bryan with Rogue Valley Urology explained what those are. "PSA stands for prostate specific antigen," said Bryan. It is made by the prostate and it can be elevated in a certain

GOLD HILL, Ore. -- A prostate cancer diagnosis can be scary for any man. Ron Brown sat down with Mike Duffy to share his story of diagnosis and treatment. He also explained why he believes early detection is so important. "At the time when they were ready to start treatment, it was up to 12," explained Brown. All of a sudden it had gone up to six and it had doubled again in six months up to 12. So it was obvious something was happening and it wasn't going back down, it was going up." A doctor's test confirmed the worst. "He did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer," detailed Brown. "It indicated it was starting to spread to the lymph nodes." Those numbers Ron referenced are called a PSA. Dr. Kadi-Ann Bryan with Rogue Valley Urology explained what those are. "PSA stands for prostate specific antigen," said Bryan. It is made by the prostate and it can be elevated in a certain

Speech to Text for New Treatments Could Help Fight Prostate Cancer Below is the closed-captioning text associated with this video. Since this uses automated speech to text spelling and grammar may not be accurate. d"a prostate cancer diagnosis can be scary for anyone. but these days, new technologies and new treatments are changing the way we look at the disease." one out of every 9 men will be diagnosed with prostate cancer in their life time. in 2018 alone, about 160 thousand men will be newly diagnosed. and every year 30 thousand men will die. but while those numbers don't sound good..there is lots of reason for hope. new medications mean growth and symptoms can be stopped or reversed in many cases. and as dr. kadi ann bryan with rogue valley urology explains, our approach is also difference these days. "fortunately, we're now beginning to recognize that a huge number of men can be treated with active surveillance. most men are likely to die with prostate c

November 29, 2018 Share this content: Men with Gleason score 9 to 10 prostate cancer derive no significant survival benefit from androgen deprivation therapy. Gleason score 9 to 10 prostate cancer (PCa) may be less sensitive to androgen deprivation therapy (ADT) than Gleason 8 disease, new study findings in European Urology suggest. Paul L. Nguyen, MD, of Harvard Medical School in Boston, and his collaborators identified 20,139 men from the National Cancer Database with localized or locally advanced Gleason score (GS) 8 to 10 PCa treated with external beam radiation therapy (EBRT) . Of these, 60% had GS 8, 36% GS 9, and 4% GS 10 disease. In addition to radiation therapy, 78% of GS 8 and 87% of GS 9 to 10 patients received ADT. Continue Reading Below ADT was associated with a significant 22% decreased risk for death among patients with GS 8 cancer, but was not associated with improved survival among patients with GS 9 to 10 cancer in multivariable analysis. As GS increased

Speech to Text for Prostate Cancer: Ron Brown's Story Below is the closed-captioning text associated with this video. Since this uses automated speech to text spelling and grammar may not be accurate. think about prostate cancer has changed dramatically in recent years. this is what one well known rogue valley resident recently found at the time when they were ready to start treatment, it was up to 12. all of a sudden it had gone up to six and it had doubled again in 6 months up to 12. and so it was obvious something was happening and it wasn't going back down, it was going up. and so that's when they did the biopsy." a doctors test confirmed the worst. he did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer. and indicated it was starting to spread to the lymph nodes." and those numbers that indicated something was going on? 1 th ey're called a psa. i asked dr. kadi ann bryan with rogue valley urology about them. ps

GOLD HILL, Ore. -- A prostate cancer diagnosis can be scary for any man. Ron Brown sat down with Mike Duffy to share his story of diagnosis and treatment. He also explained why he believes early detection is so important. "At the time when they were ready to start treatment, it was up to 12," explained Brown. All of a sudden it had gone up to six and it had doubled again in six months up to 12. So it was obvious something was happening and it wasn't going back down, it was going up." A doctor's test confirmed the worst. "He did a biopsy and took 12 samples, tissue samples and every one of them was positive for cancer," detailed Brown. "It indicated it was starting to spread to the lymph nodes." Those numbers Ron referenced are called a PSA. Dr. Kadi-Ann Bryan with Rogue Valley Urology explained what those are. "PSA stands for prostate specific antigen," said Bryan. It is made by the prostate and it can be elevated in a certain

The Loma Linda University Department of Urology has added an MRI and ultrasound fusion system for prostate biopsies, the latest development on the cutting edge of prostate cancer care.​ The new method of fusing MRI and ultrasound images improves the location accuracy of  prostate biopsies, which can minimize the number of biopsies needed for the patient and give doctors better insight on how to treat the cancer. The new approach helps doctors identify dangerous cancers to treat aggressively and allows them to monitor low-risk cancer with an active surveillance strategy.​ Urology specialist  Herbert C. Ruckle, MD, chair of Loma Linda University Health  Urology Department , says having the technology can reassure patients in the region that they have access to cutting edge and comprehensive  prostate cancer care . ​ “This keeps Loma Linda University Health at the forefront of where the specialty is at in terms of the detection and management of localized prostate cancer,” Ruckle said

Sanjeev Kaul, MD Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The hard part, Sanjeev Kaul, MD, said at the 2018 Large Urology Group Practice Association Conference, is separating the mutations that are relevant from those that are not. “Just identifying a mutation on one of these genes doesn’t necessarily mean that mutation is clinically significant,” said Kaul, associate professor of urology with Oakland University and William Beaumont Hospital in Royal Oak, Michigan. “You can have mutations across the entire BRCA1 or BRCA2 gene, but not all mutations are going to code for a protein, and not all coding mutations will actually affect the function of the gene.” Moreover, there are benefits and drawbacks to testing. With those data, physicians can administer more accurate and effective treatment while avoiding potential hazards such as administering radiation to patients with mismatch repair (MMR) gene mutations. For examp

[embedded content] Transcript: Evan Yu, MD: When you’re making a diagnosis of metastatic prostate cancer, that’s really a key event in the life of any patient. If you really think about it, there are 2 key events for someone with prostate cancer. One is when they first are diagnosed with metastatic disease on scans, and another is when they develop castration resistance. That means their testosterone level is low and their PSA [prostate-specific antigen] is rising. But the first event that I mentioned, the diagnosis of metastatic disease on scans, actually points towards the standard imaging that we use, which is with CT [computed tomography] scans and bone scans. If you look at clinical trials with the new therapeutic agents that are out there, that’s what they use: CT scans and bone scans. Certainly, there are newer imaging modalities out there—fluciclovine, PET [positron emission tomography]/CT, the PMSA [prostrate-specific membrane antigen] PET/CT—but those, at this point in tim

[embedded content] Transcript: Evan Yu, MD: When you’re making a diagnosis of metastatic prostate cancer, that’s really a key event in the life of any patient. If you really think about it, there are 2 key events for someone with prostate cancer. One is when they first are diagnosed with metastatic disease on scans, and another is when they develop castration resistance. That means their testosterone level is low and their PSA [prostate-specific antigen] is rising. But the first event that I mentioned, the diagnosis of metastatic disease on scans, actually points towards the standard imaging that we use, which is with CT [computed tomography] scans and bone scans. If you look at clinical trials with the new therapeutic agents that are out there, that’s what they use: CT scans and bone scans. Certainly, there are newer imaging modalities out there—fluciclovine, PET [positron emission tomography]/CT, the PMSA [prostrate-specific membrane antigen] PET/CT—but those, at this point in tim

The impact of cytoreductive radical prostatectomy (CRP) on oncological outcomes in patients with prostate cancer (PCa) and distant metastases has been demonstrated by retrospective data with their potential selection bias. Using prospective institutional data, we compared the outcomes between 43 PCa patients with low-volume bone metastases (1-3 lesions) undergoing CRP (median follow-up 32.7 mo) and 40 patients receiving best systemic therapy (BST; median follow-up 82.2 mo).  The inclusion criteria for both cohorts were identical. So far, no significant difference in castration resistant-free survival (p=0.92) or overall survival (p=0.25) has been detected. Compared to recent reports, the outcomes for our control group are more favorable, indicating a potential selection bias in the previous retrospective studies. Therefore, the unclear oncological effect has to be weighed against the potential risks of CRP. However, patients benefit from a significant reduction in locoregional complic

PURPOSE: We assessed the value of pelvic phased array dynamic contrast-enhanced magnetic resonance imaging for predicting the intraprostatic location and volume of clinically localized prostate cancers.  MATERIALS AND METHODS: Suspicious areas on prospective pre-biopsy magnetic resonance imaging in 24 patients were assigned a magnetic resonance imaging malignancy score and located with respect to anatomical features, gland side, and transition and peripheral zone boundaries. The largest surface area and volume were measured. These magnetic resonance imaging findings were compared with radical prostatectomy specimen histopathology findings. RESULTS: Histopathology maps detected 56 separate cancer foci. The largest tumor focus was located in the peripheral zone in 14 patients and in the transition zone in 10. T1-weighted dynamic contrast-enhanced magnetic resonance imaging identified 30 of the 39 tumor foci greater than 0.2 cc and 27 of the 30 greater than 0.5 cc. T2-weighted sequences

Treatment with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (MaxRP) or external beam radiotherapy, brachytherapy, and androgen deprivation therapy (MaxRT) provide comparable survival outcomes for men with Gleason score 9-10 prostate cancer. Limited data exist regarding how treatment with MaxRP compared with MaxRT decreases the risk of disease-specific and all-cause mortality in high-grade prostate cancer. Anthony V D’Amico, MD, PhD, department of radiation oncology, Dana-Farber Cancer Institute (Boston, MA), and colleagues conducted a study to investigate the association of these surgical and radiation approaches with mortality in patients with Gleason score 9-10 prostate cancer. A total of 639 men with clinical T1-4, N0M0 biopsy Gleason score 9-10 prostate cancer were included in the study, 80 of whom were treated with MaxRT and 559 of whom were treated with MaxRP. Researchers assessed for treatment propensity score-adjusted risk of p

Check4Cancer, a UK-based provider of screening and diagnostic cancer services, has collaborated with AXA PPP healthcare to launch a new prostate cancer diagnosis pathway. Prostate cancer is the most common cancer in men, and around 1 in 8 men are diagnosed with this disease. The conventional method of diagnosing prostate cancer involves taking small samples of tissue for analysis through needle insertion into the prostate gland via the wall of the rectum. However, this approach is uncomfortable and is actually unnecessary in several cases. Besides leading to a significant chance of a serious infection, cancer can be missed by up to 50% of the time. “With this collaboration, AXA PPP members with suspected prostate cancer can now undergo a detailed MRI of the prostate before undergoing biopsy.” Check4Cancer teamed up with AXA PPP healthcare to boost the prostate cancer diagnosis pathway for their individual, SME and large corporate members. With this collaboration, AXA PPP members

Although prostate cancer is one of the most curable types of cancer out there, it is a lot easier to treat during the earlier stages. It's hard to find it in the early stages, however, if you aren't experiencing any particularly signs that it might be happening. That being said, there are subtle changes in your body that you may notice overall if you pay close attention. If you do notice any of the following early signs, Dr. Bruce Sloane, practicing urology physician in Philadelphia, said that a prostate-specific antigen (PSA) test is the only sure indicator of early stages of prostate cancer. According to the Prostate Cancer Foundation , when a problem within the prostate arises, typically more PSA is released, and higher amounts of PSA can be detected in the bloodstream. Dr. Sloane suggests men over the age of 60 get their PSA levels checked. Here are five early signs of prostate cancer. https://ift.tt/2PXBdiO

‘Movember’ was organized in 2004 to raise awareness of men’s health issues, particularly cancer and depression. As this Movember comes to an end, it’s not too late to discuss cancer risks particular to men. Article continues below... Rob Johnston, Wyoming Cancer Resource Services Regional Coordinator-Region II at the Casper-Natrona County Health Department, has provided Oil City News with three fact sheets on colorectal, prostate and testicular cancer. Colorectal Cancer Colorectal cancer is the second leading cause of cancer death in the United States. Colorectal cancer is preventable with appropriate screening. Colorectal cancer has no symptoms in the early stages. 45% of all Wyoming residents over the age of 50 have colon polyps that can turn into cancer over time. The Wyoming Cancer Program offers free at-home colorectal screening tests, known as FIT kits. This is an easy way to screen for colorectal cancer. • FIT stands for fecal immunochemical test • It detects hidden

A clinical trial could be the world’s first to look at personalised medicine in prostate cancer, with patients taking a therapy based on their DNA markers… A new clinical trial, opening across  Canada , is considered a major advancement in precision medicine for prostate cancer and thought to be the first of its kind in the world. The IND.234 clinical trial, conducted by the  Canadian Cancer Trials Group (CCTG) , will use liquid biopsy technology to screen for genomic markers in prostate cancer patients. After the liquid biopsy analysis, patients with specific DNA markers are assigned to one of five new therapies targeted at their unique form of prostate cancer. Researchers want to see if the markers identified in the screening process can help predict which patients will be helped the most by the targeted treatments. “There is an urgent need to find more effective therapies for men with advanced prostate cancer and an individual’s cancer is unique, so a one-size-fits-all solutio

Popular YouTube videos on prostate cancer often mislead patients seeking medical screening and treatment information, according to a new study led by researchers at NYU School of Medicine and its Perlmutter Cancer Center. The study, published Tuesday in  European Urology , found that 77% of the 150 most-viewed YouTube videos on prostate cancer contained factual errors or biased content that posed health risks to patients. One video, for example, promoted injecting herbs into the prostate. The practice can be harmful to patients and is not backed by medical evidence. Other videos were outdated and promoted aggressive treatments not considered necessary, according to the study. "The real shocking finding for me was this discord between the scientific quality and the user engagement," said the study's senior investigator, Dr. Stacy Loeb, an assistant professor in the urology and population health departments at NYU School of Medicine. "That's really concerning to

Check4Cancer, a UK-based provider of screening and diagnostic cancer services, has collaborated with AXA PPP healthcare to launch a new prostate cancer diagnosis pathway. Prostate cancer is the most common cancer in men, and around 1 in 8 men are diagnosed with this disease. The conventional method of diagnosing prostate cancer involves taking small samples of tissue for analysis through needle insertion into the prostate gland via the wall of the rectum. However, this approach is uncomfortable and is actually unnecessary in several cases. Besides leading to a significant chance of a serious infection, cancer can be missed by up to 50% of the time. “With this collaboration, AXA PPP members with suspected prostate cancer can now undergo a detailed MRI of the prostate before undergoing biopsy.” Check4Cancer teamed up with AXA PPP healthcare to boost the prostate cancer diagnosis pathway for their individual, SME and large corporate members. With this collaboration, AXA PPP members

[embedded content] Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer. Researchers learned 4 years ago that the addition of docetaxel to androgen deprivation therapy (ADT) improved overall survival in patients with newly diagnosed metastatic disease; this was reported in the pivotal phase III CHAARTED trial. Conducted in the United Kingdom, the multi-arm STAMPEDE trial evaluated the addition of abiraterone acetate (Zytiga) plus prednisone to ADT in patients with relapsed prostate cancer. This trial confirmed the findings of CHAARTED; the addition of chemotherapy to ADT improved patient outcomes, Burgess says. The use of abiraterone acetate in combination with ADT has also been evaluated in patients with metastatic castration-sensitive prostate cancer. The randomized phase III LATITUDE trial showed that the addition of abiraterone acetate to ADT at the time

Dealing with Cancer for yourself or a loved one is difficult and Prostate Cancer is no different. Alexa recently visited the Cleveland Clinic where she spoke with Dr. Tendukar, a Radiation Oncologist, who knows all about the different types of treatment when dealing with prostate cancer. While he may not have all the answers, his advice on how to deal with the side effects of treatment are very helpful to those struggling. For More Information: clevelandclinic.org/prostatecancer © 2018 WKYC https://ift.tt/2FK225x

E fforts to save lives by detecting cancer earlier have stalled because British patients are fearful of wasting GPs’ time, a report has found. A major review concludes that thousands of deaths could be avoided each year if the UK were to match international cancer standards, but that progress is being hampered due in part to embarrassment over troubling busy family doctors with what seem like minor symptoms. The Health Foundation report said more than a fifth of patients are worried about wasting their doctor’s time. Meanwhile nearly half put off checking out symptoms because of difficulty securing an appointment. A shortage of scanners and specialist staff to operate them are also blamed in the document, written by the NHS’s former cancer chief Professor Sir Mike Richards. Britain currently ranks 35th out of 37 comparable nations for availability of CT scanners, and 31st out of 36 for MRI scanners. Sir Mike writes that the lag behind international best practice represents a

If you’re a smoker looking for another reason to quit, consider this: in addition to raising your risk of heart and lung disease, as well as cancers of the bladder and kidney, smoking could boost the odds that you will develop aggressive prostate cancer that metastasizes, or spreads through your body. That’s according to research published by an Austrian team in 2018. The evidence connecting tobacco use with prostate cancer (which tends to grow relatively slowly) isn’t as strong as it is for other smoking-related diseases. Researchers first detected the link only after pooling data from 51 studies that enrolled over four million men. Published in 2014 , this earlier research showed that smokers have a 24% higher risk of death from prostate cancer than nonsmokers, but it left an open question: did the men who died from these other causes also have high-grade prostate cancers that had not yet been detected? Experts suspected that since smoking kills in different ways, some of those who